Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Siegfried acquires three drug substance sites

PRIVATEAug 21, 2026about 3 hours ago

Acquiring Company

Siegfried AG

Acquired Company

Extractas Bioscience

SwitzerlandTasmaniaManufacturingBiotechnologyPharmaceuticalManufacturingBiotechnology

Description

Siegfried AG has completed the acquisition of three drug substance sites in the US and Australia effective May 1, 2026. This strategic acquisition strengthens Siegfried's manufacturing capabilities and is expected to contribute approximately USD 100 million in net sales for 2026. The integration of the new sites is progressing smoothly, enhancing the company's capacity to support early-phase development to commercial manufacturing. Siegfried continues to execute its growth strategy while focusing on operational excellence.

Company Information

Company

Siegfried AG

Location

Switzerland

About

Siegfried AG is a global leader in the pharmaceutical industry, focused on the development and manufacturing of high-quality drug substances and products. The company provides services that support customers from early-phase development to commercial manufacturing. With a clear emphasis on operational excellence, Siegfried is committed to sustainable value creation. The company executes its strategies through targeted mergers and acquisitions to enhance its growth.

Don't miss Siegfried AG's next move

Get an email the moment Siegfried AG makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Sara
Senior decision-maker at this company
••••••••@••••••••

See Sara's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Siegfried AG's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Extractas Bioscience?

Extractas Bioscience was acquired by Siegfried AG, based in Switzerland. The deal was reported on August 21, 2026. Siegfried AG is a global leader in the pharmaceutical industry, focused on the development and manufacturing of high-quality drug substances and products. Siegfried AG is privately held and operates in Manufacturing.

When did Siegfried AG acquire Extractas Bioscience?

Siegfried AG's acquisition of Extractas Bioscience was reported on August 21, 2026. Siegfried AG has completed the acquisition of three drug substance sites in the US and Australia effective May 1, 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Extractas Bioscience do?

Extractas Bioscience specializes in the extraction and processing of high-quality plant-derived substances for pharmaceutical applications. The company contributes several technological and operational capabilities that enhance drug substance manufacturing. It is privately held, operating in Manufacturing, and is based in Tasmania.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.